Journey Medical (DERM) Liabilities and Shareholders Equity (2020 - 2026)

Journey Medical (DERM) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $91.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 7.74% year-over-year to $91.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $352.5 million (up 19.71% YoY) and the FY2025 annual result came in at $94.6 million, up 17.88% from the prior year.
• Liabilities and Shareholders Equity declined to $91.5 million in Q1 2026, from $94.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $120.9 million in Q1 2022 to a low of $64.0 million in Q3 2024.
• A 5-year average of $86.4 million and a median of $85.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 39.05% — and 2025, when it surged 33.02%.
• Tracing DERM's Liabilities and Shareholders Equity over 5 years: stood at $105.2 million in 2022, then slipped by 26.92% to $76.8 million in 2023, then increased by 4.41% to $80.2 million in 2024, then advanced by 17.88% to $94.6 million in 2025, then dropped by 3.23% to $91.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $91.5 million (Q1 2026), $94.6 million (Q4 2025), and $85.2 million (Q3 2025), per Business Quant data.